Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$3.67M$3.67Mderivedno prior Q4 2020 on file Net Income-$6.27M-$6.27MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$4,040,000N/M Operating Cash Flowderived-$3,880,000N/M Free Cash Flowderived-$3,998,000— Margins · derivedOperating margin-110.2%
Net margin-171.1%
ended Dec 31, 2021 · filed Mar 24, 2022 · 83 d after period end